Migraine and Endometriosis: The FEMININE Study
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorHospital Universitari Vall d'Hebron Research Institute
About this trial
Migraine and endometriosis are common conditions that mainly affect females of reproductive age. Both can cause significant pain and have a strong impact on the quality of life. Increasing evidence suggests that these two conditions often occur together, and that females who have both may experience more severe symptoms than those with only one of them. However, the reasons why migraine and endometriosis are linked are still not well understood.
Some biological factors may help explain this connection. One of them is a molecule called calcitonin gene-related peptide (CGRP), which plays an important role in migraine and may also be involved in pain and inflammation in endometriosis. In addition, hormonal changes during the menstrual cycle, especially fluctuations in estrogen levels, may influence symptoms in both conditions. Genetic and epigenetic factors may also contribute to this association.
The main hypothesis of this study is that females who have both migraine and endometriosis have a distinct clinical and biological profile compared to females who have only migraine or only endometriosis. In particular, it is expected that differences will be observed in CGRP levels and hormonal patterns across the menstrual cycle.
The FEMININE study is a prospective observational study that will follow females over several menstrual cycles. It will include three groups: females with both migraine and endometriosis, females with migraine only, and females with endometriosis only. Participants will record their symptoms in diaries and will provide blood samples at specific times of the menstrual cycle.
The main goal of the study is to compare CGRP levels between groups. Additional goals include describing differences in symptoms, menstrual-related migraine, hormonal levels, and selected genetic and epigenetic markers.
By improving the understanding of how migraine and endometriosis are related, this study aims to support better diagnosis and more personalized care for females affected by these conditions.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult females (≥18 years old).
Diagnosis of migraine according to ICHD-3 criteria confirmed by a headache specialist (for MIG-O and MIG-EDM groups).
Confirmed diagnosis of endometriosis based on clinical symptoms and imaging or surgical criteria according to ESHRE guidelines (for EDM-O and MIG-EDM groups).
Signed informed consent.
Disqualifiers
Individuals diagnosed with secondary headache according to the ICHD-3.
Individuals with a severe disease (e.g., major psychiatric disorder, severe cardiovascular conditions).
History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months.
Pregnant or breastfeeding females.
Trial population
Participants will be recruited from prospectively maintained clinical databases at Vall d'Hebron University Hospital (Headache Unit and Gynecology Unit) and from outpatient clinics specialized in migraine and endometriosis. The study population consists of adult females of reproductive age with a diagnosis of migraine, endometriosis, or both, who are receiving routine clinical care at a tertiary referral center.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
150 Participants
are grouped into 3 trial groupsGroup A: Migraine and Endometriosis (MIG-EDM)
Group B: Migraine Only (MIG-O)
Group C: Endometriosis Only (EDM-O)
Trial outcomes
Primary outcomes
1
Pattern of serum CGRP levels across menstrual phases
Serum CGRP levels measured during the periovulatory and perimenstrual phases and compared among females with comorbid migraine and endometriosis, migraine only, and endometriosis only.
Time frame
During the first 3 menstrual cycles, up to 6 months if extension is neededSecondary outcomes
1
Migraine frequency
Monthly headache days recorded in the headache diary.
Time frame
Baseline through completion of follow-up, up to 6 months2
Acute medication use
Number of acute medication intake days per month recorded in the headache diary.
Time frame
Baseline through completion of follow-up, up to 6 months3
Migraine-related disability
Headache Impact Test-6 (HIT-6) score in participants with migraine.
Time frame
Baseline and end of study, up to 6 months4
Menstrually related migraine features
Prevalence and clinical characteristics of menstrually related migraine based on diary data.
Time frame
During follow-up, up to 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: